Notable from Our Podcast

In the August 13, 2019, podcast interview, Dr. Jason Crowell talks with Dr. Michele Hu and Dr. David Okai about their longitudinal study of the severity of impulse control disorders in Parkinson disease and RBD.

NPub.org/podcast

Author Tip

E-alerts

Want to easily keep track of new articles published in Neurology in your field of interest? Sign up for e-alerts! You can customize alerts to be emailed to you about new articles by subject, title, and author. You can also get the table of contents of all, or some, of the Neurology journals. To sign up for e-alerts, please visit NPub.org/alerts.

From the AAN Press Room

Visit AAN.com/pressroom for the latest press releases

Common Drugs Tied to Increased Risk of Cognitive Decline

A class of drugs used for many conditions, including allergies, colds, high blood pressure, and depression, may be associated with an increased risk of developing mild thinking and memory problems, particularly in people who have genetic risk factors for Alzheimer disease or markers of this condition. The study found that cognitively normal people taking at least one anticholinergic drug were 47% more likely to develop mild cognitive impairment, which can be a precursor to dementia, over the next decade than people who were not taking such drugs. “Our findings suggest that reducing the use of anticholinergic drugs before people develop any cognitive problems may be an important way to prevent the negative consequences of these drugs on thinking skills, especially for people who have an elevated risk of developing Alzheimer disease,” said study author Lisa Delano-Wood, Ph.D., of the University of California, San Diego.

Association of anticholinergic medication and AD biomarkers with incidence of MCI among cognitively normal older adults doi.org/10.1212/WNL.0000000000010643

CME

Global prevalence and burden of HIV-associated neurocognitive disorder: A meta-analysis

Page 854

Small fiber pathology in autism and clinical implications

Page 862